Cansortium (OTCMKTS:CNTMF – Get Free Report) and Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) are both healthcare companies, but which is the superior stock? Get Cansortium alerts:Analyst RecommendationsThis is a summary of recent recommendations and price targets for Cansortium and Kiora Pharmaceuticals, as provided by MarketBeat.com. Given Kiora Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Cansortium. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cansortium N/A N/A N/A N/A N/A Kiora Pharmaceuticals $16.02 million 0.73 -$10.84 million ($2.71) -0.97Cansortium has higher earnings, but lower revenue than Kiora Pharmaceuticals. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021.